News Release

Leading minds of tomorrow recognized today

American Psychiatric Association and AstraZeneca launch international awards programme

Grant and Award Announcement

Shire Health International

The American Psychiatric Association (APA) and AstraZeneca announced today the launch of their 2003 'Young Minds in Psychiatry International Awards Programme', an annual commitment by the two organisations to recognize and support promising young psychiatrists from across the globe.

Four unrestricted career development awards of $45,000 (USD) will be available to psychiatry researchers working in the fields of bipolar disorder and schizophrenia. The winners will also be invited to attend an award ceremony at the APA's Young Investigators meeting in New York held as part of their annual congress in May 2004.

Building on the success of the first Young Minds in Psychiatry Awards Programme held in 2002, Darrel Regier, MD, Executive Director of APIRE (American Psychiatric Institute for Research and Education) commented, "The quality of the applications received in 2002 was outstanding and we are pleased to be collaborating with AstraZeneca again this year to provide this vital career development support to young psychiatry researchers."

Nigel Doran, Global Marketing Director, AstraZeneca remarked, "We are dedicated to providing medicines that can make a real impact on the lives of people with disorders of the Central Nervous System. These awards will support innovative research and career development in this specialised field and will ultimately lead to improved treatment options for patients."

To apply for a Young Minds in Psychiatry Award, candidates are requested to submit a proposal of scientific merit demonstrating academic promise and how winning an Award will assist in the advancement of their career. Proposals can cover a range of activities including: research, educational efforts, travel, salary support and materials. All applications will be reviewed by the APIRE and a panel of distinguished psychiatrists.

The closing date for the 2003 APA/AstraZeneca Young Minds in Psychiatry Awards Programme is October 14, 2003.

###

Notes to Editors:
Further information can be found at http://www.psych.org/res_res/youngminds_announce.cfm or www.astrazeneca.com/youngminds. All applicants must have completed their psychiatric residency within the last five years. The APA/AstraZeneca Young Minds in Psychiatry Awards Programme has evolved from the Young Minds in CNS Program, previously run by AstraZeneca alone.

American Psychiatric Association
The American Psychiatric Association is a national medical specialty society, founded in 1844, whose 38,000 physician members specialize in the diagnosis, treatment and prevention of mental illnesses including substance use disorders.

AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with leading positions in sales of gastrointestinal, oncology, anaesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products. In CNS, AstraZeneca is dedicated to providing medicines, which have the potential to change patients' lives. The company's investments in research are aimed toward developing solutions - medicines with greater effectiveness and fewer side effects.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.